We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted pr... Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications. Show more
Objective response rate of 69.2% observed in heavily pretreated patient population including patients with BTK inhibitor resistance mutations Clinical responses in CLL patients were rapid and...
SAN FRANCISCO, June 10, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to...
Period † | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 2.16 | 11.6254036598 | 18.58 | 22.4388 | 18.1759 | 1621831 | 20.96514702 | CS |
4 | 5.43 | 35.4670150229 | 15.31 | 22.4388 | 14.44 | 1224988 | 17.95831717 | CS |
12 | 5.99 | 40.6101694915 | 14.75 | 22.4388 | 11.9 | 1181700 | 15.97910646 | CS |
26 | 10.81 | 108.86203424 | 9.93 | 22.4388 | 7.65 | 977388 | 13.97970452 | CS |
52 | 10.97 | 112.282497441 | 9.77 | 22.4388 | 4.22 | 745985 | 11.79634463 | CS |
156 | -9.16 | -30.635451505 | 29.9 | 37.425 | 4.22 | 520000 | 14.60793803 | CS |
260 | 0.49 | 2.41975308642 | 20.25 | 52.38 | 4.22 | 471795 | 17.50996456 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions